Previous 10 | Next 10 |
A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA ® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% i...
Amarin Corporation plc (AMRN) Cowen 42nd Annual Health Care Conference March 07, 2022 9:10 AM ET Company Participants Karim Mikhail - President & Chief Executive Officer Conference Call Participants Ken Cacciatore - Cowen Presentation Ken Cacciatore 00:02 Great, thanks so much David for p...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2021 Q4 earnings call. For further details see: Amarin Corporation plc 2021 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q4 2021 Earnings Call Mar 01, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q4 2021 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q4 2021 Earnings Conference Call March 01, 2022 08:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations & Corporate Affairs Karim Mikhail - President & Chief Executive Officer Mike Kalb - Chief Financial Officer Confe...
Amarin (NASDAQ:AMRN) rose pre-market after its Q4 results beat analysts' estimates. Full year 2021 total net revenue decreased 5.03% Y/Y to $583.19M. Net product revenue fell 4% Y/Y to $580.32M. The company said the decrease was driven mainly by volume of heart drug VASCEPA sales to its ...
Amarin press release (NASDAQ:AMRN): Q4 Non-GAAP EPS of $0.06 beats by $0.09. Revenue of $144.49M (-13.6% Y/Y) beats by $2.32M. As of December 31, 2021, Amarin reported aggregate cash and investments of $489.1 million, consisting of cash and cash equivalents of $219.5 million and liquid s...
Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approva...
Amarin (NASDAQ:AMRN) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.03 (vs $0.04 in Q420) and the consensus Revenue Estimate is $142.17M (-15.0% Y/Y). Amarin's Q3 revenue missed Wall Street estimates, hurt by the decli...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care C...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...